AbbVie (ABBV) Change in Accured Expenses (2012 - 2026)

AbbVie (ABBV) has reported Change in Accured Expenses for 15 consecutive years, with -$1.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 129.02% year-over-year to -$1.6 billion; the TTM figure through Mar 2026 stood at $53.0 million (up 106.02% YoY), while the FY2025 annual figure was $951.0 million, up 437.29% from the prior year.
• Change in Accured Expenses fell to -$1.6 billion in Q1 2026 per ABBV's latest filing, from -$598.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.5 billion in Q3 2023 and bottomed at -$1.7 billion in Q2 2024.
• Historically, Change in Accured Expenses has averaged $302.5 million across 5 years, with a median of $267.0 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 363.89% — and 2023, when it soared 928.42%.
• AbbVie's Change in Accured Expenses stood at $1.3 billion in 2022, then plunged by 85.99% to $179.0 million in 2023, then jumped by 596.65% to $1.2 billion in 2024, then slumped by 147.96% to -$598.0 million in 2025, then slumped by 166.56% to -$1.6 billion in 2026.
• Business Quant data shows ABBV's Change in Accured Expenses at -$1.6 billion in Q1 2026, -$598.0 million in Q4 2025, and $1.7 billion in Q3 2025.